 "Our business model is to acquire and form companies around
undervalued assets identified from
a highly focused analysis of issued
patents in regenerative medicine
that have demonstrated proof of
concept" 
Dr. Ichim is one of the leading authorities in the world on stem cell biology.
"A STEM CELL INCUBATOR COMPANY"
With an emphasis on stem cell regenerative medicine
52wk Range:
0.06 - 0.0002 | OS 1,752,000,000 as per TA for today Thursday, Apr 25, 2013 | | | Shares Outstanding:Authorized 2 Billion
| | | |
| 
(Wholly-Owned Susidiary of BMSN)
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.  (Wholly-Owned Susidiary of BMSN)
Entest BioMedical Inc. (OTCBB: ENTB)is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues. Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment. Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms. Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.
MANAGEMENT TEAM | REGEN BIOPHARMA, INC.
David R. Koos, PhD, DBA Chairman and Chief Executive Officer
David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.
J. Christopher Mizer President and Chief Operating Officer
Christopher Mizer is the founder of Vivaris, Ltd. and serves as President and Chief Executive Officer. Vivaris invests in and acquires middle-market businesses that are leaders in their market niches. Mr. Mizer serves as a director of each of the portfolio companies and guides key strategic decisions and their execution. He also serves as the operating president on an interim basis when companies are going through periods of ownership succession and new management team members are being assembled.
Mr. Mizer is a former Vice President and Officer of the investment banking division of Key Capital Markets, where he focused on merger, acquisition, and financing projects for Fortune 500 clients, private companies, and successful entrepreneurs. Prior to joining Key Corp., he was a consultant and certified public accountant with Ernst & Young. He earned the B.S. and M.S. degrees (biology) and B.A. (economics) and MBA (finance and accounting) degrees from Case Western Reserve University.
Thomas E. Ichim, PhD
Chief Scientific Officer and Director of Research
Dr. Ichim is one of the leading authorities in the world on stem cell biology. To date, he has published 82 peer-reviewed articles and is co-editor of the textbook RNA Interference: From Bench to Clinical Translation. He is also inventor on over 30 patents and patent applications. He currently serves as the CEO of Medistem, Inc., was formerly chief of scientific development, and is the scientific founder / co-founder of Medvax Pharma, ToleroTech, bioRASI, and OncoMune.
ADVISORY BOARD | REGEN BIOPHARMA, INC. {C}{C}{C}{C}{C}{C}{C}{C} Weiping Min, M.D. Dr. Min is Associate Professor, Department of Surgery at the University of Western Ontario. His clinical research is focused on using siRNA to inhibit disease modalities, including cancer and organ rejection. He earned graduate and medical degrees from Nanchang University Medical School and the Ph.D. degree from Kyushu University.
Vladimir Bogin M.D. Dr. Bogin is the President and CEO of Cromos Pharma, a contract research organization that specializes in biopharmaceutical clinical outsourcing. He was formerly the Director of Boehringer Ingelheim in charge of the phase IV program for Dabigatran Etexilate. He studied at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry.
David James Graham White, M.D., Ph.D. Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and Ph.D. degrees from Cambridge University. | 
OUR APPROACH | REGEN BIOPHARMA, INC
Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies.
COMMERCIALIZATION 
FDA FILING HemaXellerate™
[Regen intends to file an Investigational New Drug (IND) Application in the fourth quarter of 2012 ]
patent No. 6,821,513 http://www.prweb.com/releases/2012/10/prweb9972993.htm
HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally." Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).
White Papers:
Journal of Translation Medicine
http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf
OPERATIONAL PLAN "STEMCELL INCUBATOR COMPANY" - Month 1-2: Assembly of Team. Regen intends to assemble a team of world-class leaders in the spheres of Technology, Intellectual Property assessment, valuation and Clinical development. Regen will seek to compile a team of Physician-Scientists with experience in the area of clinical trials for regenerative medicine/stem cell products, Regulatory experts who have successfully taken products through the FDA and corresponding agencies internationally, and Biotech Entrepreneurs who have track records of excellence in business formation and value optimization. -DONE
- Month 1-4: In-licensing of Intellectual Property. The Company having already assessed over 20,000 issued patents and having compiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses on issued patents that have already passed preclinical studies but are not under clinical development. -DONE
- Month 3-6: Interaction with Regulatory Agencies. Regen intends to develop data packages for each of the technologies and initiate interaction with Regulatory Agencies such as the FDA for initiation of trials.-DONE (CLINARTIS)
- Month 6-18: Clinical Implementation. Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy. NEXT UP
- Month 18-24: Exit. It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline.
- "At present there exists a wealth of intellectual property that is 'collecting dust' in the corridors of Academia. Given the field of regenerative medicine and stem cell therapy is so young, and the business models are fuzzy at best in terms of valuation, we see this space as a unique opportunity for acceleration of clinical development/value optimization," said Bio-Matrix Chairman & CEO David Koos about its Regen BioPharma. "Valuations for stem cell companies that have passed the threshold of clinical safety, with signals of efficacy are astronomical. The $1.8 billion Mesoblast-Cephalon deal, as well as recent financings of private companies with as little as 3 patient data such as Promethera ($31 million) or Allocure with 16 patients ($23 million), is testimony to the extremely high valuations that are characteristic of this space."
IBOX BY MONEYMADE 12/30 ABOUT Bio-Matrix | Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) is based in San Diego, California and is a publicly trade company biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs. | Meet the Bio-Matrix Management Team Corporate Headquarters Bio-Matrix Scientific Group Inc. 8885 Rehco Road San Diego, California 92122 U.S.A. Phone: Fax: (619)325-0702 http://www.bmsn.us David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO Dr. Koos has been involved with investment banking, venture capital, and investor relations for more than 20 years. He is the Chairman, CEO, and acting CFO of Bio-Matrix Scientific Group, Inc. He has worked with major Wall Street investment banks and was a Vice-President of Investments with Sutro & Co., Everen Securities, and Dean Witter. In addition, Dr. Koos holds a Ph.D. degree in Economic Sociology, a DBA in Corporate Finance, both from Atlantic International University. In addition, Dr. Koos holds M.A. degree in Economic Sociology from the University of California, Riverside, California.
EWA CARRIER, M.D. - Associate Professor of Clinical Medicine and Pediatrics
University of California San Diego
Blood and Marrow Transplant Program
Feng Lin, MD, PhD - Director of Research Dr. Feng Linhas a strong background in drug/DNA in vivo delivery, oncology and tumor immunotherapy, cell and molecular biology, and animal model work. He also has extensive experience with tissue imaging, and stem cell differentiation. Previously, Dr. Lin was a Senior Research Scientist, Research & Development with Inovio BC, San Diego and Postdoctoral Fellow in the Burnham Institute for Medical Research, La Jolla. He received his M.D. from Central South University Xiangya School of Medicine, Changsha, China, along with a M.S. Biochemistry & Molecular Biology and a Ph.D. Hematology & Physiology from the same institution. Dr. Lin's research work has been widely published in international scientific journals.
Marilyn Panahi - Director of Quality Assurance
MS. Panahi brings more than 15 years experience in the implementation and management of the EPA's Good Laboratory Practice Standards (GLPS) Compliance Monitoring Program and the FDA's Good Manufacturing Practices (GMP)/Quality Systems Regulation.Previously, Ms. Panahi was Quality Manager, Therapheresis, Inc., San Diego. Ms. Panahi is a graduate of San Diego State University with a B.S. in Microbiology. Ms. Panahi also holds a Certificate in Science of Regulatory Affairs for the Drug and Biologic Industry and a Certificate in Quality Assurance/Control for the Drug and Biologic Industry, both from the University of California at San Diego.
|  | PARTNERS :
CLINARTIS
MEDISTEM
CASCADE LIFESCIENCES INC.
SUSIDIARIES
Regen BioPharma Inc.
Entest Biomedical, Inc (Symbol: ENTB)
|  | The Endometrial Regenerative Cells (ERCs) Regen use are owned by MEDS. Dr. Lewis pretty much states thats these stems cells are superior to the 'gold standard' of Stem Cells, Bone Marrow Stem Cells. According to this document the NIH agrees http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212625/pdf/1479-5876-5-57.pdf Thomas E. Ichim, PhD the new Chief Scientific Officer and Director of Research is also CEO of Medistem
Dr. Ichim is one of the leading authorities in the world on stem cell biology. To date, he has published 82 peer-reviewed articles and is co-editor of the textbook RNA Interference: From Bench to Clinical Translation. He is also inventor on over 30 patents and patent applications. He currently serves as the CEO of Medistem, Inc., was formerly chief of scientific development, and is the scientific founder / co-founder of Medvax Pharma, ToleroTech, bioRASI, and OncoMune.
Medistem, Inc., is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States.
ERCs have several distinguishing advantages to other stem cell therapies: a) Non-invasive method of collection; b) Unlimited supply of cells; isolated from menstrual blood of young healthy donors; c) Economical and scalable to manufacture; d) Exert higher therapeutic activity compared to other stem cells; and e) demonstrated safe in animal and pilot human studies.
Endometrial Regenerative Cells
| | Cascade LifeSciences Incorporated | Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate™ product using mice models for testing. Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study. The results of Regen's study will provide the safety profile data required for filing of an Investigational New Drug (IND) application for the product with the US Food and Drug Administration . Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014. HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."
Howard Civian Birndorf is a biotechnology entrepreneur and one of the founders of the biotech industry in San Diego, California.[1] Along with former University of California professor and current venture capitalist Ivor Royston, Birndorf founded San Diego's first biotech in 1978, the monoclonal antibody company Hybritech. The company was subsequently bought by Eli Lilly and Company in 1986, and Birndorf went on to found a number of other successful companies including Gen-Probe, IDEC Pharmaceuticals (which merged with Biogen to form Biogen-Idec), and Ligand. Birndorf was also involved in the formation of Gensia (Sicor), was a founding investor of Kiyon, and was a founding Director of Neurocrine Biosciences. Birndorf was Chairman of the Board and founding Director of FasTraQ, Chairman of HA Cell Technology and was Chairman of Oy Jurilab, a Finnish genomics company. He is a founder and co-chair of the Coalition for 21st Century Medicine and was founder, Chairman and CEO of Nanogen, Inc. Birndorf received his B.A. in Biology from Oakland University, an M.S. in Biochemistry from Wayne State University, and has received honorary Doctor of Science degrees from Oakland University and Wayne State University.
Cascade Lifesciences
http://www.ohsu.edu/xd/research/techtransfer/startups/2008-ohsu-startup-companies.cfm | | CLINARTIS | Agreement with Clinartis: Contract Research Organization from 5/30/12
The objective of this LOI is to express the intent of Clinartis and Regen BioPharma to establish a strategic mutually beneficial relationship for the purpose of identifying, assessing, and securing intellectual property for regenerative medicine applications, executing product development including the conduct of clinical trials in associated therapeutic applications, and the preparation and execution of regulatory strategies leading to product commercialization.
Parties agree that in the course of identifying, assessing, and securing intellectual property for regenerative medicine applications, executing product development including the conduct of clinical trials in associated therapeutic applications and the preparation and execution of regulatory strategies Clinartis will provide services to Regen Pharma, which will include, but not limited to, the following:
Assessment of the probability of clinical and regulatory success, and commercial potential of intellectual property; | |